Richard Wilson is currently the Senior Vice President, Primary Focus Lead of Genetic Regulation at Astellas and is responsible for setting and leading the AAV gene therapy strategy for Astellas’ Primary Focus Genetic Regulation. Richard joined Audentes Therapeutics (now Astellas Gene Therapies) in April 2020 as Vice President, Program Management. Richard has over 30 years of experience in research, development, and commercialization of small molecules, biological and gene therapies. Prior to Astellas , he served as portfolio Core Team leader for BioMarin’s PKU franchise, overseeing the approval and global launch of the first enzyme substitution therapy for PKU. Prior to BioMarin, Richard held leadership positions in GlaxoWellcome, BioChem Pharma, Theravance and Innoviva, where he was involved in the development and commercialization of a range of products in COPD and Asthma, and led R&D programs in anti-infective, cardiovascular, rheumatology, and urology disease areas. Richard holds a BSc (Hons) in Chemistry from the University of Manchester and an MBA from the Haas School of Business at the University of California, Berkeley, and is currently a member of the board of directors of the Alliance for Regenerative Medicine.